Curaleaf (OTCMKTS:CURLF) Shares Gap Up – Here’s What Happened

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shares gapped up prior to trading on Thursday . The stock had previously closed at $9.19, but opened at $9.83. Curaleaf shares last traded at $9.67, with a volume of 13,799 shares.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CURLF shares. Zacks Research upgraded shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Citigroup reaffirmed a “buy” rating on shares of Curaleaf in a research note on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Curaleaf Trading Down 2.9%

The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.52. The stock has a market capitalization of $2.23 billion, a P/E ratio of -73.44 and a beta of 1.56. The stock has a 50-day moving average price of $7.38 and a two-hundred day moving average price of $7.82.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.25. Curaleaf had a negative return on equity of 0.88% and a negative net margin of 2.62%.The company had revenue of $340.10 million during the quarter, compared to the consensus estimate of $332.00 million. On average, research analysts forecast that Curaleaf Holdings, Inc. will post -0.04 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.